Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CM9.0000000000003765 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.
Front Oncol
August 2025
Department of Hematology, General Hospital of the Northern Theater Command, Shenyang, China.
Objective: Chimeric antigen receptor T-cell immunotherapy (CAR-T) is a preferred treatment for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Several trials have evaluated CD20×CD3 bispecific antibodies (BsAbs) as subsequent therapy in R/R LBCL. This study aimed to investigate the efficacy of CD20×CD3 BsAbs (mosunetuzumab, glofitamab, odronextamab, and epcoritamab) in patients with LBCL who experienced relapse or refractory disease following CAR-T therapy.
View Article and Find Full Text PDFCombination of gemox, lenvatinib, and PD-1 blockade vs. gemox monotherapy as first-line treatment for intrahepatic cholangiocarcinoma with metastases.
Chin Med J (Engl)
September 2025
Department of Ultrasound Diagnose, the First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.
Lancet Oncol
August 2025
Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. Electro
Background: The optimal conversion regimen that allows more patients with unresectable biliary tract cancer to access surgery remains unclear; there is currently no standard conversion therapy for biliary tract cancer in China, with commonly used regimens including immunotherapy-based combinations and local therapy. The ZSAB-TransGOLP study aimed to assess the efficacy and safety of tislelizumab plus lenvatinib and GEMOX (gemcitabine plus oxaliplatin) chemotherapy (GOLP) in patients with this disease.
Methods: This single-arm, phase 2 study was conducted at two centres in China.
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
Blood
August 2025
Roche Innovation Center Zurich, Schlieren, Switzerland.
T cell engagers (TCEs) are transformative therapeutics in hematological malignancies, including non-hodgkin lymphoma (NHL). Initially approved for relapsed/refractory disease settings, TCEs are now explored in first-line and second-line settings, often combined with standard-of-care (SOC) treatments, including chemotherapy and anti-drug conjugates (ADCs). This study investigates glofitamab (CD20xCD3 T cell engager) combinations in preclinical humanized lymphoma models, addressing heterogeneity of tumor antigen expression, immune evasion, and T cell exhaustion.
View Article and Find Full Text PDFPathological complete response in advanced intrahepatic cholangiocarcinoma was achieved through tri-modal therapy: A case report and review of literature.
World J Gastrointest Oncol
July 2025
Department of General Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, Guangdong Province, China.
Background: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with limited treatment options and a poor prognosis, particularly in unresectable or metastatic cases. Tri-modal strategies combining systemic chemotherapy, targeted therapies, and immune checkpoint inhibitors have demonstrated synergistic effects in converting unresectable ICC to resectable status and improving patient survival.
Case Summary: A 39-year-old male presented with unresectable stage IIIB ICC (cT3N1M0), abdominal pain, and elevated carbohydrate antigen (CA) 19-9 levels.